Finerenone and flozins in CKD

Jürgen Floege, MD, is a senior professor at the RWTH Aachen University Medical School, Germany. He served as head of the Division of Nephrology and Immunology at Aachen for 24 years. He coordinates the worldwide KDIGO guidelines on the management of glomerular diseases. His research interests encompass both basic research and clinical research.

Would you say that finerenone has a comparable position as flozins in the treatment of patients with chronic kidney disease (CKD)?

Jürgen Floege, MD: I can answer that question with definitive evidence in two years because the key study, the FIND-CKD study, is still ongoing where, like with sodium-glucose cotransporter 2 (SGLT-2) inhibitors, they include diabetic and nondiabetic CKD. But in all likelihood... and there’s no reason to believe why finerenone shouldn’t work in nondiabetic kidney disease because aldosterone is relevant for every kidney disease. It’s one of the hormones that really propagate kidney scarring.